Check out other pages at BiotechDueDiligence for an intro to Complete Genomics GNOM as well as info on the GNOM merger with BGI and the role Illumina ILMN is playing in that deal. Continue reading below for relevant highlights from the ILMN 3q-2012 earnings conference call.
Add Comment The recently launched biotech opinion portal PropThink published a bullish piece on Complete Genomics $GNOM on November 23, 2012 entitled “Limited Downside With Potential Bidding War Upside For GNOM” (link). PropThink publishes high-quality research but I disagree with the author David Moskowitz in this case, as I detail below... See below for ILMN earnings conference call quotes courtesy of Seeking Alpha transcript, with some minor edits for clarity (analyst questions are in italics). Illumina $ILMN and Complete Genomics $GNOM are two keys players in the business of providing contract-based human whole genome sequencing. Disclosure: I am currently long GNOM shares. Pacific Biosciences stock ($PACB) continues to trade below net cash value, but continues to struggle financially as their try to establish their business in the highly competitive sequencing market. The company reported earnings on 7/26/2012 and sold only one sequencing in the second quarter (not a surprise though based on previous commentary). We'll have more info from the conference call shortly, but for now review the history and business of PACB, courtesy of contributor Dale Yuzuki (read much more of Dale's work on his blog). Disclosures: No position in PACB for the author or Editor of BiotechDueDiligence. | Please consider a contribution in support of the site
 CategoriesAll ArchivesJune 2013 |
RSS Feed